Fact Sheet
Immunovaccine Inc. (TSX-V: IMV)
- Incorporated in 2000
- Corporate headquarters in Halifax, Nova Scotia, Canada
- 20+ employees
- Developer of patented DepoVax™ vaccine enhancement and delivery platform
- Phase I human clinical trial for ovarian, breast and prostate cancer vaccine to begin Q1 2010
- Licensing agreements and key partnerships with leading biotech organizations including Pfizer Animal Health, La Jolla Institute for Allergy & Immunology (LIAI), National Institutes of Health (NIH), Bioject Inc., Defence Research & Development Canada, FIT Biotech, Scancell Ltd, Immunotope Inc. and Yokohoma City University
- Proven manufacturing scale up capabilities at a Health Canada approved cGMP facility
